Hospital Acquired Bacterial Pneumonia (HABP)

Infectious Diseases
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BioVersys
BioVersysSwitzerland - Basel
1 program
1
BV100Phase 31 trial
Active Trials
NCT07326540Not Yet Recruiting248Est. Mar 2028

Trial Timeline

Clinical trial activity over time

2026
2027
2028
BioVersysBV100

Clinical Trials (1)

Total enrollment: 248 patients across 1 trials

Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

Start: Mar 2026Est. completion: Mar 2028248 patients
Phase 3Not Yet Recruiting

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space